Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2012

View Archived Issues

New S1P1 receptor ligands presented by researchers at Allergan

Fixed-dose combination drug evaluated in seasonal allergic and chronic rhinitis

Preclinical and phase I results presented for MLN-4924

First-in-human data presented on PD-1-targeted cancer immunotherapy

Otsuka and Kyowa Hakko Kirin to form strategic alliance

FAS-specific antibody for arthritis shows promise in first clinical trial

Multiple early-stage trials of MLN-9708 presented

OSI Pharmaceuticals divulges novel focal adhesion kinase inhibitors

German company discloses new muteins of human lipocalin

Marshall Edwards changes name

Janssen completes acquisition

Somatuline approved in Japan

New agents for hypercholesterolemia designed in Japan

Gilead submits NDA to FDA for AIDS drug

Pfizer patents novel kynurenine aminotransferase II inhibitors

Scientists at Biomay report new hypoallergenic vaccines

Novel antiviral agents developed

GABA(A) receptor modulator improves sleep in human model of insomnia

Laurantis Pharma presents phase I data on eye drop therapy

GSK and Theravance report on phase III COPD trials

Affymetrix expands product portfolio with acquisition

Japanese phase I study of SO-1105 complete

Bristol-Myers Squibb plans acquisition

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...